Nuveen
PRLD icon

Nuveen’s Prelude Therapeutics PRLD Stock Holding History

Nuveen’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$197K Buy
+37,023
New +$161K ﹤0.01% 3646
2025
Q2 		– Sell
-187,613
Closed -$3.62M – 3376
2025
Q1 		$3.62M Buy
187,613
+170,816
+1,017% +$159K ﹤0.01% 2080
2024
Q4 		$21.4K Hold
16,797
– – ﹤0.01% 3322
2024
Q3 		$34.8K Hold
16,797
– – ﹤0.01% 3328
2024
Q2 		$64K Hold
16,797
– – ﹤0.01% 3320
2024
Q1 		$79.6K Hold
16,797
– – ﹤0.01% 3257
2023
Q4 		$71.7K Buy
16,797
+2,993
+22% +$9.11K ﹤0.01% 3297
2023
Q3 		$42.7K Hold
13,804
– – ﹤0.01% 3160
2023
Q2 		$62.1K Buy
+13,804
New +$82.5K ﹤0.01% 3184
2022
Q2 		– Sell
-66,421
Closed -$490K – 3439
2022
Q1 		$490K Buy
66,421
+25,904
+64% +$237K ﹤0.01% 3024
2021
Q4 		$504K Sell
40,517
-4,882
-11% -$79.4K ﹤0.01% 3072
2021
Q3 		$1.42M Buy
45,399
+8,240
+22% +$267K ﹤0.01% 2832
2021
Q2 		$1.06M Sell
37,159
-187
-0.5% -$6.66K ﹤0.01% 2982
2021
Q1 		$1.62M Buy
37,346
+2,624
+8% +$174K ﹤0.01% 2711
2020
Q4 		$2.48M Buy
+34,722
New +$1.73M ﹤0.01% 2404

Other funds holding PRLD

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Nuveen's PRLD Position: Q2 2026 in Review

Nuveen opened a new position in Prelude Therapeutics (PRLD) in Q2 2026: 37,023 shares worth $197K. The stake represents ﹤0.01% of the portfolio and ranks #3646 among its holdings. This is a return to the name: Nuveen previously reported a position in PRLD as recently as Q1 2025.

Nuveen first reported a position in PRLD in Q4 2020 and has held it in 15 quarters since. The position peaked at $3.62M in Q1 2025. 75 funds tracked by Wall St. Rank hold PRLD as of Q2 2026.

  • Nuveen held 37,023 shares of Prelude Therapeutics worth $197K as of Q2 2026.
  • Prelude Therapeutics was a new Nuveen position in Q2 2026.
  • Prelude Therapeutics made up ﹤0.01% of Nuveen's portfolio in Q2 2026, its #3646 holding.
  • Nuveen first reported a position in Prelude Therapeutics in Q4 2020 and has held it in 15 quarters since.
  • Nuveen's Prelude Therapeutics position peaked at $3.62M in Q1 2025.
  • 75 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.